Avalo Therapeutics (STU:C6K0) Inventories, Raw Materials & Components: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:C6K0 Avalo Therapeutics Inc STU:C6K0
44 GF Score
Price €15.76
GF Value €0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics Inventories, Raw Materials & Components?

Avalo Therapeutics STU:C6K0 -4.83% 44 Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:C6K0 with a GF Score™ of 44/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Avalo Therapeutics's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €0.00 Mil.

Avalo Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Inventories, Raw Materials & Components Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Avalo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:C6K0
44GF Score
Avalo Therapeutics Inc STU:C6K0
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €0.00 Mil mean?
Avalo Therapeutics (STU:C6K0) has a Inventories, Raw Materials & Components of €0.00 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Avalo Therapeutics and its competitors.
Is Avalo Therapeutics' Inventories, Raw Materials & Components too high?
Avalo Therapeutics' current Inventories, Raw Materials & Components is €0.00 Mil. Overall, Avalo Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avalo Therapeutics' Inventories, Raw Materials & Components compare to SANA and ANRO?
Avalo Therapeutics' Inventories, Raw Materials & Components of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Avalo Therapeutics and its competitors. Avalo Therapeutics's current Inventories, Raw Materials & Components is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Avalo Therapeutics (STU:C6K0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €15.76 — trading 52433.3% above its estimated fair value. The current Inventories, Raw Materials & Components is €0.00 Mil. Avalo Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Avalo Therapeutics (STU:C6K0), the current Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Avalo Therapeutics (STU:C6K0) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of €15.76 is trading 52433.3% above its estimated GF Value™ of €0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:C6K0:

  • Inventories, Raw Materials & Components: €0.00 Mil
  • GF Value™: €0.03 vs. price of €15.76 (52433.3% above fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the STU:C6K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avalo Therapeutics Business Description

Other Exchanges AVTX:USA
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
44GF Score

Get the complete analysis for STU:C6K0

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.76
Price
€0.03
GF Value